JP2003533537A - タンパク質の誘導体化 - Google Patents

タンパク質の誘導体化

Info

Publication number
JP2003533537A
JP2003533537A JP2001585141A JP2001585141A JP2003533537A JP 2003533537 A JP2003533537 A JP 2003533537A JP 2001585141 A JP2001585141 A JP 2001585141A JP 2001585141 A JP2001585141 A JP 2001585141A JP 2003533537 A JP2003533537 A JP 2003533537A
Authority
JP
Japan
Prior art keywords
protein
derivatization
compound
reaction
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001585141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003533537A5 (https=
Inventor
グレゴリー グレゴリアディス
Original Assignee
リポクセン テクノロジーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リポクセン テクノロジーズ リミテッド filed Critical リポクセン テクノロジーズ リミテッド
Publication of JP2003533537A publication Critical patent/JP2003533537A/ja
Publication of JP2003533537A5 publication Critical patent/JP2003533537A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
JP2001585141A 2000-05-16 2001-05-14 タンパク質の誘導体化 Pending JP2003533537A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00304108.4 2000-05-16
EP00304108 2000-05-16
PCT/GB2001/002115 WO2001087922A2 (en) 2000-05-16 2001-05-14 Derivatisation of proteins in aqueous solution

Publications (2)

Publication Number Publication Date
JP2003533537A true JP2003533537A (ja) 2003-11-11
JP2003533537A5 JP2003533537A5 (https=) 2008-06-05

Family

ID=8172993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001585141A Pending JP2003533537A (ja) 2000-05-16 2001-05-14 タンパク質の誘導体化

Country Status (8)

Country Link
US (1) US6962972B2 (https=)
EP (1) EP1335931B1 (https=)
JP (1) JP2003533537A (https=)
AT (1) ATE313554T1 (https=)
AU (1) AU2001258536A1 (https=)
DE (1) DE60116137T2 (https=)
ES (1) ES2256234T3 (https=)
WO (1) WO2001087922A2 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501888A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド ポリシアル酸誘導体
JP2007501889A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のためのシアル酸誘導体
JP2008510024A (ja) * 2004-08-12 2008-04-03 リポクセン テクノロジーズ リミテッド 分別
JP2008531764A (ja) * 2005-02-23 2008-08-14 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のための活性化シアル酸誘導体
JP2009544677A (ja) * 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド 顆粒球コロニー刺激因子の誘導体化
JP2013500375A (ja) * 2009-07-27 2013-01-07 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
JP2016113626A (ja) * 2009-07-27 2016-06-23 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016168A2 (en) * 2004-08-12 2006-02-16 Lipoxen Technologies Limited Sialic acid derivatives
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
JP2010520320A (ja) 2007-02-28 2010-06-10 リポクセン テクノロジーズ リミテッド ポリシアル酸におけるエンドトキシンの低減
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
DK2598172T3 (da) 2010-07-30 2019-07-01 Baxalta GmbH Nukleofile katalysatorer til oximforbindelse
EP3808378A1 (en) 2011-05-27 2021-04-21 Baxalta GmbH Therapeutic proteins with increased half-life and methods of preparing same
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
DK2804623T3 (da) 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
HRP20200007T1 (hr) 2012-07-11 2020-03-20 Bioverativ Therapeutics Inc. Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
SG10201710616XA (en) 2013-06-28 2018-02-27 Biogen Ma Inc Thrombin cleavable linker with xten and its uses thereof
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
US20180022780A1 (en) 2014-09-26 2018-01-25 Bayer Pharma Aktiengesellschaft Stabilization adrenomedullin derivatives and use thereof
ES2753391T3 (es) 2014-10-14 2020-04-08 Halozyme Inc Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
CA3007364A1 (en) 2015-12-03 2017-06-08 Baxalta Incorporated Factor viii with extended half-life and reduced ligand-binding properties
EA201892249A1 (ru) 2016-04-04 2019-05-31 Шайр Хьюман Дженетик Терапиз, Инк. Конъюгированный ингибитор c1-эстеразы и пути его применения
JP7464530B2 (ja) 2018-03-28 2024-04-09 ブリストル－マイヤーズ スクイブ カンパニー インターロイキン－２／インターロイキン－２受容体アルファ融合タンパク質および使用方法
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
CA3104686A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf-21 formulations
CA3143584A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501889A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のためのシアル酸誘導体
JP2007501888A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド ポリシアル酸誘導体
JP2012082436A (ja) * 2004-08-12 2012-04-26 Lipoxen Technologies Ltd 電荷を有する多糖の分別
JP2008510024A (ja) * 2004-08-12 2008-04-03 リポクセン テクノロジーズ リミテッド 分別
JP2014169451A (ja) * 2004-08-12 2014-09-18 Lipoxen Technologies Ltd 電荷を有する多糖の分別
JP2008531764A (ja) * 2005-02-23 2008-08-14 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のための活性化シアル酸誘導体
JP2014114315A (ja) * 2006-07-25 2014-06-26 Lipoxen Technologies Ltd エリスロポエチンの多糖誘導体
US8981050B2 (en) 2006-07-25 2015-03-17 Lipoxen Technologies Limited N-terminal derivatisation of proteins with polysaccharides
US10300144B2 (en) 2006-07-25 2019-05-28 Lipoxen Technologies Limited N-terminal polysialylation
US8394921B2 (en) 2006-07-25 2013-03-12 Lipoxen Technologies Limited N-terminal derivatisation of proteins with polysaccharides
JP2013049675A (ja) * 2006-07-25 2013-03-14 Lipoxen Technologies Ltd Ｎ末端ポリシアリル化
JP2013100309A (ja) * 2006-07-25 2013-05-23 Lipoxen Technologies Ltd エリスロポエチンの多糖誘導体
JP2013121982A (ja) * 2006-07-25 2013-06-20 Lipoxen Technologies Ltd ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2013241446A (ja) * 2006-07-25 2013-12-05 Lipoxen Technologies Ltd ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2009544680A (ja) * 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2009544677A (ja) * 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド 顆粒球コロニー刺激因子の誘導体化
JP2015007062A (ja) * 2006-07-25 2015-01-15 リポクセン テクノロジーズ リミテッド Ｎ末端ポリシアリル化
JP2009544681A (ja) * 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド エリスロポエチンの多糖誘導体
JP2015145400A (ja) * 2006-07-25 2015-08-13 リポクセン テクノロジーズ リミテッド ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2018039791A (ja) * 2006-07-25 2018-03-15 リポクセン テクノロジーズ リミテッド エリスロポエチンの多糖誘導体
JP2016128493A (ja) * 2006-07-25 2016-07-14 リポクセン テクノロジーズ リミテッド ポリサッカライドによるタンパク質のｎ末端誘導体化
US9492556B2 (en) 2006-07-25 2016-11-15 Lipoxen Technologies Limited N-terminal derivatisation of proteins with polysaccharides
JP2017018107A (ja) * 2006-07-25 2017-01-26 リポクセン テクノロジーズ リミテッド エリスロポエチンの多糖誘導体
US9789163B2 (en) 2006-07-25 2017-10-17 Lipoxen Technologies Limited N-terminal derivatisation of proteins with polysaccharides
US9795683B2 (en) 2009-07-27 2017-10-24 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
JP2018024882A (ja) * 2009-07-27 2018-02-15 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
JP2016113626A (ja) * 2009-07-27 2016-06-23 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
JP2013500375A (ja) * 2009-07-27 2013-01-07 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
US10772968B2 (en) 2009-07-27 2020-09-15 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
JP2022058911A (ja) * 2009-07-27 2022-04-12 バクサルタ インコーポレイテッド 非血液凝固タンパク質の糖ポリシアル酸化

Also Published As

Publication number Publication date
DE60116137T2 (de) 2006-08-24
ES2256234T3 (es) 2006-07-16
EP1335931B1 (en) 2005-12-21
DE60116137D1 (de) 2006-01-26
US20030129159A1 (en) 2003-07-10
AU2001258536A1 (en) 2001-11-26
WO2001087922A2 (en) 2001-11-22
ATE313554T1 (de) 2006-01-15
WO2001087922A3 (en) 2003-05-30
US6962972B2 (en) 2005-11-08
EP1335931A2 (en) 2003-08-20

Similar Documents

Publication Publication Date Title
JP2003533537A (ja) タンパク質の誘導体化
JP5586669B2 (ja) Ｎ末端ポリシアリル化
Jain et al. Polysialylated insulin: synthesis, characterization and biological activity in vivo
EP0063109B1 (en) Therapeutically active compound and pharmaceutical composition containing the same
EP0973806B1 (en) Site protected protein modification
EA008505B1 (ru) Конъюгаты химически модифицированного гормона роста человека
JP2007501888A (ja) ポリシアル酸誘導体
JP2012116840A (ja) タンパク質ポリエチレングリコール（ｐｅｇ）複合体形成を増大させる方法
Zhang et al. Site-selective glycosylation of hemoglobin on Cys β93
Fehske et al. Direct demonstration of the highly reactive tyrosine residue of human serum albumin located in fragment 299–585
KR20060136463A (ko) 폴리에틸렌 글리콜(ｐｅｇ) 단백질 결합을 증가시키기 위한방법
Ladd et al. Reagents for the preparation of chromophorically labeled polyethylene glycol-protein conjugates
JPH05340948A (ja) 鶏卵抗体固定化担体およびその固定化方法
Veronese et al. Preparation and properties of monomethoxypoly (ethylene glycol)-modified enzymes for therapeutic applications
FR2496692A1 (fr) Procede de dosage de la peroxyde dismutase
Ito et al. Design and synthesis of a protein device that releases insulin in response to glucose concentration
Valdivia et al. Improved pharmacological properties for superoxide dismutase modified with β-cyclodextrin–carboxymethylcellulose polymer
JP2628310B2 (ja) 酵素の安定化方法
JPH05261281A (ja) 生理活性物質固定化担体とその製法
Fu et al. Methionine modification impairs the C5‐cleavage function of cobra venom factor‐dependent C3/C5 convertase
Mahbouba et al. Thiolation and disulphide cross-linking of insulin to form macromolecules of potential therapeutic value
Odajima et al. A chemical modification of myeloperoxidase and lactoperoxidase with 2‐(O‐methoxypolyethylene glycol)‐4, 6‐dichloro‐s‐triazine (activated PEG1)
CN118373870A (zh) 一种基于醛基巯基反应的蛋白偶联方法
JPH05345022A (ja) 生理活性物質固定化担体とその製法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110308